2-AG Enhancing Compositions for Migraine Relief
Summary
The USPTO granted Patent US12599600B2 to Arizona Board of Regents on Behalf of the University of Arizona for compositions and methods enhancing 2-arachydonyl glycerol (2AG) activity to prevent and treat headaches, particularly migraines. The patent covers methods for reducing prostaglandin activity and includes claims for pharmaceutical compositions containing 2AG-enhancing compounds.
What changed
The USPTO issued Patent US12599600B2 for compositions and methods enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity to prevent, reduce occurrence of, or treat headaches including migraines. The patent lists 5 claims covering pharmaceutical compositions and treatment methods.\n\nFor pharmaceutical companies and medical device manufacturers, this patent establishes intellectual property rights that may restrict development of similar 2AG-enhancing migraine therapies without licensing. Parties conducting research in endocannabinoid-based pain treatment should conduct freedom-to-operate analyses to assess potential infringement risks.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity
Grant US12599600B2 Kind: B2 Apr 14, 2026
Assignee
Arizona Board of Regents on Behalf of the University of Arizona
Inventors
Tally M. Largent-Milnes, Erika Liktor-Busa, Todd W. Vanderah, Nephi Stella
Abstract
This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject.
CPC Classifications
A61K 31/454 A61K 31/496 A61K 45/06 A61K 2300/00 A61P 25/06
Filing Date
2021-05-26
Application No.
17331025
Claims
5
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.